JP2025515205A5 - - Google Patents
Info
- Publication number
- JP2025515205A5 JP2025515205A5 JP2024566263A JP2024566263A JP2025515205A5 JP 2025515205 A5 JP2025515205 A5 JP 2025515205A5 JP 2024566263 A JP2024566263 A JP 2024566263A JP 2024566263 A JP2024566263 A JP 2024566263A JP 2025515205 A5 JP2025515205 A5 JP 2025515205A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- substituted
- sequence
- adc
- adc according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022091860 | 2022-05-10 | ||
| CNPCT/CN2022/091860 | 2022-05-10 | ||
| CN202310390683.5 | 2023-04-13 | ||
| CN202310390683 | 2023-04-13 | ||
| PCT/CN2023/092968 WO2023217133A1 (en) | 2022-05-10 | 2023-05-09 | Antibody-drug conjugates comprising an anti-folr1 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515205A JP2025515205A (ja) | 2025-05-13 |
| JP2025515205A5 true JP2025515205A5 (enExample) | 2026-05-19 |
Family
ID=88729697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566263A Pending JP2025515205A (ja) | 2022-05-10 | 2023-05-09 | 抗ｆｏｌｒ１抗体を含む抗体－薬物コンジュゲート |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4522223A1 (enExample) |
| JP (1) | JP2025515205A (enExample) |
| CN (1) | CN119855616A (enExample) |
| AU (1) | AU2023267043A1 (enExample) |
| CA (1) | CA3252704A1 (enExample) |
| TW (1) | TW202400247A (enExample) |
| WO (1) | WO2023217133A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026035986A1 (en) | 2024-08-07 | 2026-02-12 | Bighat Biosciences, Inc. | Humanized anti-cdh17 antibodies and use of the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6871858B2 (ja) * | 2015-01-28 | 2021-05-19 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 抗体薬物コンジュゲート |
| US20170224835A1 (en) * | 2015-02-06 | 2017-08-10 | Sorrento Therapeutics, Inc. | Antibody Drug Conjugates |
| CN108285487B (zh) * | 2017-01-08 | 2021-02-19 | 浙江昭华生物医药有限公司 | 抗5t4抗体-药物偶联物及其应用 |
| JP7359700B2 (ja) * | 2017-06-20 | 2023-10-11 | ソレント・セラピューティクス・インコーポレイテッド | Ｃｄ３８抗体薬物コンジュゲート |
| JP7623939B2 (ja) * | 2018-07-09 | 2025-01-29 | マルチチュード インコーポレーテッド | 葉酸受容体アルファに特異的な抗体 |
| WO2022184082A1 (en) * | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
-
2023
- 2023-05-09 TW TW112117172A patent/TW202400247A/zh unknown
- 2023-05-09 EP EP23802902.9A patent/EP4522223A1/en active Pending
- 2023-05-09 CN CN202380039566.2A patent/CN119855616A/zh active Pending
- 2023-05-09 AU AU2023267043A patent/AU2023267043A1/en active Pending
- 2023-05-09 JP JP2024566263A patent/JP2025515205A/ja active Pending
- 2023-05-09 CA CA3252704A patent/CA3252704A1/en active Pending
- 2023-05-09 WO PCT/CN2023/092968 patent/WO2023217133A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI864472B (zh) | 抗體的特異性偶聯 | |
| JP7853711B2 (ja) | チューブリシン類縁体と細胞結合分子との共役体の製剤 | |
| TWI851552B (zh) | 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物 | |
| US10391181B2 (en) | Cyclodextrin and antibody-drug conjugate formulations | |
| JP7262817B2 (ja) | 分岐連結体を備えたチューブリシン類縁体の共役体 | |
| JP2024112832A (ja) | 分岐連結体を有する細胞結合分子と細胞毒性剤との共役体 | |
| CN115443134A (zh) | 细胞结合分子与喜树碱类似物的偶联物 | |
| WO2022228493A1 (zh) | 抗体偶联药物的制备方法及应用 | |
| JP2024059609A (ja) | タンパク質中のグルタミン残基にコンジュゲートされたカンプトテシンアナログおよびその使用 | |
| TWI909461B (zh) | 抗體-藥物偶聯物靶向治療前列腺癌和其他腫瘤 | |
| CA3128264A1 (en) | A conjugate of an amanita toxin with branched linkers | |
| JP2023529640A (ja) | 治療用コンジュゲート | |
| JP2025509286A5 (enExample) | ||
| WO2023186015A1 (zh) | B7h4抗体药物偶联物及其用途 | |
| JP2024509169A5 (enExample) | ||
| KR20200070254A (ko) | 면역접합체에서 메티오닌 산화를 방지하는 방법 | |
| TWI753252B (zh) | 含支鏈連接體的Ｔｕｂｕｌｙｓｉｎ同系物偶聯物 | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP2025504477A (ja) | 抗組織因子抗体－薬物コンジュゲートを含む医薬組成物 | |
| KR102544135B1 (ko) | c-Kit을 표적으로 하는 면역접합체 | |
| WO2026026912A1 (zh) | 抗体药物偶联物和抗vegf抗体的联合应用 | |
| WO2026056990A1 (zh) | 抗体药物偶联物联合vegfr tki和/或蒽环类药物治疗癌症的用途 | |
| EA052527B1 (ru) | Конъюгат лекарственное средство-антитело к b7h4 и его применение | |
| WO2025054312A1 (en) | Hla-g antibodies in antibody-drug conjugates | |
| BR112020025212B1 (pt) | Derivado de dímero de pirrolobenzodiazepina cruzadamente ligado, conjugado de um derivado de dímero de pirrolobenzodiazepina cruzadamente ligado a uma molécula de ligação à célula, l1 e l2, agente de ligação à célula/molécula de ligação à célula, célula tumoral, composição farmacêutica, e, agentes quimioterapêutico e sinérgicos |